240 related articles for article (PubMed ID: 36739065)
1. Noncoding RNAs in the crosstalk between multiple myeloma cells and bone marrow microenvironment.
Tang W; Xu J; Xu C
Cancer Lett; 2023 Mar; 556():216081. PubMed ID: 36739065
[TBL] [Abstract][Full Text] [Related]
2. Exosomal miRNAs in the Tumor Microenvironment of Multiple Myeloma.
Alipoor SD; Chang H
Cells; 2023 Mar; 12(7):. PubMed ID: 37048103
[TBL] [Abstract][Full Text] [Related]
3. MicroRNAs and exosomes: Small molecules with big actions in multiple myeloma pathogenesis.
Pourhanifeh MH; Mahjoubin-Tehran M; Shafiee A; Hajighadimi S; Moradizarmehri S; Mirzaei H; Asemi Z
IUBMB Life; 2020 Mar; 72(3):314-333. PubMed ID: 31828868
[TBL] [Abstract][Full Text] [Related]
4. The Role of Marrow Microenvironment in the Growth and Development of Malignant Plasma Cells in Multiple Myeloma.
Giannakoulas N; Ntanasis-Stathopoulos I; Terpos E
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33923357
[TBL] [Abstract][Full Text] [Related]
5. Exosomal mRNAs and lncRNAs involved in multiple myeloma resistance to bortezomib.
Tang JX; Chen Q; Li Q; He YH; Xiao D
Cell Biol Int; 2021 May; 45(5):965-975. PubMed ID: 33372728
[TBL] [Abstract][Full Text] [Related]
6. Old and Young Actors Playing Novel Roles in the Drama of Multiple Myeloma Bone Marrow Microenvironment Dependent Drug Resistance.
Manni S; Carrino M; Semenzato G; Piazza F
Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29783691
[TBL] [Abstract][Full Text] [Related]
7. MicroRNAs: Novel Crossroads between Myeloma Cells and the Bone Marrow Microenvironment.
Raimondi L; De Luca A; Morelli E; Giavaresi G; Tagliaferri P; Tassone P; Amodio N
Biomed Res Int; 2016; 2016():6504593. PubMed ID: 26881223
[TBL] [Abstract][Full Text] [Related]
8. NRF2 Is One of the Players Involved in Bone Marrow Mediated Drug Resistance in Multiple Myeloma.
Yen CH; Hsiao HH
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30405034
[TBL] [Abstract][Full Text] [Related]
9. Bone Marrow Stromal Cells-Induced Drug Resistance in Multiple Myeloma.
Ria R; Vacca A
Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31963513
[TBL] [Abstract][Full Text] [Related]
10. miRNAs and Multiple Myeloma: Focus on the Pathogenesis, Prognosis, and Drug Resistance.
Tavakoli Pirzaman A; Ebrahimi P; Hasanpour AH; Shakeri M; Babajani B; Pourali Ganji Z; Babaei H; Rahmati A; Hosseinzadeh R; Doostmohamadian S; Kazemi S
Technol Cancer Res Treat; 2023; 22():15330338231202391. PubMed ID: 37728167
[TBL] [Abstract][Full Text] [Related]
11. Wnt signaling in multiple myeloma: a central player in disease with therapeutic potential.
Spaan I; Raymakers RA; van de Stolpe A; Peperzak V
J Hematol Oncol; 2018 May; 11(1):67. PubMed ID: 29776381
[TBL] [Abstract][Full Text] [Related]
12. Repurposing tofacitinib as an anti-myeloma therapeutic to reverse growth-promoting effects of the bone marrow microenvironment.
Lam C; Ferguson ID; Mariano MC; Lin YT; Murnane M; Liu H; Smith GA; Wong SW; Taunton J; Liu JO; Mitsiades CS; Hann BC; Aftab BT; Wiita AP
Haematologica; 2018 Jul; 103(7):1218-1228. PubMed ID: 29622655
[TBL] [Abstract][Full Text] [Related]
13. Modeling multiple myeloma-bone marrow interactions and response to drugs in a 3D surrogate microenvironment.
Belloni D; Heltai S; Ponzoni M; Villa A; Vergani B; Pecciarini L; Marcatti M; Girlanda S; Tonon G; Ciceri F; Caligaris-Cappio F; Ferrarini M; Ferrero E
Haematologica; 2018 Apr; 103(4):707-716. PubMed ID: 29326121
[TBL] [Abstract][Full Text] [Related]
14. Dissecting the multiple myeloma-bone microenvironment reveals new therapeutic opportunities.
Shay G; Hazlehurst L; Lynch CC
J Mol Med (Berl); 2016 Jan; 94(1):21-35. PubMed ID: 26423531
[TBL] [Abstract][Full Text] [Related]
15. Emerging roles of noncoding RNAs in multiple myeloma: A review.
Yang Q; Shen X; Su Z; Ju S
J Cell Physiol; 2019 Jun; 234(6):7957-7969. PubMed ID: 30370557
[TBL] [Abstract][Full Text] [Related]
16. Molecular Crosstalk between Chromatin Remodeling and Tumor Microenvironment in Multiple Myeloma.
Chakraborty C; Mukherjee S
Curr Oncol; 2022 Dec; 29(12):9535-9549. PubMed ID: 36547163
[TBL] [Abstract][Full Text] [Related]
17. Realization of Osteolysis, Angiogenesis, Immunosuppression, and Drug Resistance by Extracellular Vesicles: Roles of RNAs and Proteins in Their Cargoes and of Ectonucleotidases of the Immunosuppressive Adenosinergic Noncanonical Pathway in the Bone Marrow Niche of Multiple Myeloma.
Watanabe T
Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34199285
[TBL] [Abstract][Full Text] [Related]
18. Multiple myeloma cells promote migration of bone marrow mesenchymal stem cells by altering their translation initiation.
Dabbah M; Attar-Schneider O; Zismanov V; Tartakover Matalon S; Lishner M; Drucker L
J Leukoc Biol; 2016 Oct; 100(4):761-770. PubMed ID: 27272311
[TBL] [Abstract][Full Text] [Related]
19. Novel therapeutic strategies for multiple myeloma.
Mimura N; Hideshima T; Anderson KC
Exp Hematol; 2015 Aug; 43(8):732-41. PubMed ID: 26118499
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of Drug Resistance in Relapse and Refractory Multiple Myeloma.
Yang WC; Lin SF
Biomed Res Int; 2015; 2015():341430. PubMed ID: 26649299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]